Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.
Brief Summary: Part 1 (Phase 1): safety and tolerability of bevacizumab-Niraparib combination Part 2 (Randomized Phase 2): to compare Progression-Free Survival (PFS)

PARP inhibitors are active as monotherapy to treat patients with recurrent ovarian cancer; the strongest activity being observed in the platinum sensitive, gBRCAmut subgroup as well as in gBRCAwt, HRD population but also in HRD negative disease.

In the same population there is level one evidence that bevacizumab is beneficial. And a phase two randomized study has indicated that combination of a PARP inhibitor with anti-angiogenic drug is superior to PARP inhibitor alone.

The question is:

Is niraparib combined with bevacizumab superior to niraparib? The comparison of tolerability and efficacy of niraparib-bevacizumab combination against niraparib.


Options:
A: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental
C: Arm Label: Bevacizumab + Paclitaxel + Carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel, Drug: Bevacizumab, Drug: Carboplatin | Arm Label: Placebo + Paclitaxel + Carboplatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Bevacizumab + Paclitaxel + Carboplatin, Placebo + Paclitaxel + Carboplatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Paclitaxel + Carboplatin
D: Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Research Arm; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: PLD, Biological: Bevacizumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Research Arm | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): Research Arm | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Research Arm

Answer: A